WELLVONE

This brand name is authorized in Australia, Estonia, Spain, France, Netherlands, United Kingdom, South Africa

Active ingredients

The drug WELLVONE contains one active pharmaceutical ingredient (API):

1 Atovaquone UNII Y883P1Z2LT - ATOVAQUONE

Atovaquone is a selective and potent inhibitor of the eukaryotic mitochondrial electron transport chain in a number of parasitic protozoa and the parasitic fungus P. jiroveci. The site of action appears to be the cytochrome bc1 complex (complex III). Read about Atovaquone

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
WELLVONE Oral suspension	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
P01AX06	Atovaquone	P Antiparasitic products, insecticides and repellents → P01 Antiprotozoals → P01A Agents against amoebiasis and other protozoal diseases → P01AX Other agents against amoebiasis and other protozoal diseases
Discover more medicines within P01AX06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 8300W
Country: EE	Ravimiamet	Identifier(s): 1773110
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 63390
Country: FR	Base de données publique des médicaments	Identifier(s): 66955317
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 165909
Country: NL	Z-Index G-Standaard	Identifier(s): 14249642
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 47147
Country: ZA	Health Products Regulatory Authority	Identifier(s): 31/20.2.6/0033